Similarly, a study showed that triple blockade of HER2/HER3 signaling using trastuzumab, pertuzumab, and patritumab could overcome resistance to trastuzumab therapy in heregulin-expressing and HER2-positive breast cancer [100]. This evidence concerns the gene ERBB2 and breast carcinoma.